Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Omer Shvili who wrote (1197)	8/30/1998 1:44:00 PM
From: Timothy Kross	Respond to of 1491

Omar: I agree with your post 100%. The situation reminds me of the quote Peter Lynch gave in his book, "One up on Wall Street." He said lots of people have the brains to make money on Wall Street but that few people have the guts to make money on Wall Street. How many of us have the intestinal fortitude to buy more Pharmos after it has plunged so far so fast? I do. The value is there for all to see. Thank you for your post.

To: Omer Shvili who wrote (1197)	8/30/1998 1:49:00 PM
From: wolfdog2	Respond to of 1491

Omer, well said!

To: Omer Shvili who wrote (1197)	8/30/1998 1:49:00 PM
From: Shlepper	Respond to of 1491

Omer - well said, I'm one of the few happy campers around because I agree with your assessment and am buying more at these depressed prices. There are lots of opportunities around, but PARS seems to be a safe bet with blockbuster potential. Anyway, I've been in for some time, and will accumulate and hold for 3 years - as you said, one must be patient. Good Luck

To: Omer Shvili who wrote (1197)	8/30/1998 9:35:00 PM
From: arnie h	Read Replies (2) \| Respond to of 1491

Omer: Thanks for a great summary and before I take issue with one point, let me note I just got 5 copies of the annual report because I hold PARS in 5 separate accounts. The area of my concern is with your point that nobody knows the results of HU211. You then proceed to make a case for the company knowing that the results are positive. I have to say it makes me nervous when there is a hint that people know the results of double blind studies before they are unblinded. It turns out the FDA in this country tends to penalize firms who do this. As a long term investor myself, I tend to want to avoid any unneccessary delays that might result from such an event. Hopefully, the company is acting in a fashion that involves contingency planning rather than active knowledge. Regardless, PARS should be a minimum of $6 or so by the next millenium which as you pointed out ain't too bad. Regards, Arnie

To: Omer Shvili who wrote (1197)	8/31/1998
From: Ariella	Read Replies (1) \| Respond to of 1491

Dear Omer, Great post. Share this article with the PARS team in Israel, especially the last paragraph. ALREX could be a big drug if Ruder Finn and the co-marketer handle it right. biz.yahoo.com Shalom, Ariella

To: Omer Shvili who wrote (1197)	8/31/1998 5:32:00 PM
From: Richard Huth	Respond to of 1491

Omer, thank you for your posting. What a happy day for the ones who are long. Staying in positive territory all day while the financial world around is sinking in ashes is a sedative for our distressed nerves. Not knowing what would come later on I used the early hours to add some more shares to my portfolio, and now I am even more happy to see (at least for today :-) ), that I have not been wrong. But as nearly everyone here I see PARS as a longterm investment. But I can understand when investors are getting nervous, and I am not going to blame them. If one was fully invested 3 month ago and does not have the chance to use these prices to average down, the losses are frightening. Even taking into account a possible 50 % increase after publishing positive data on HU211, based on $ 1,75 this would lead to $ 2,625 - still far below the year's high. On the long run PARS has more than only one good reason for an increasing share price on its side. You mentioned them all. But I want to stress one reason, that was mentioned only aside: The economical crisis might have a big impact on the worldwide economy, and what we have seen right now might only just be the start. But PARS, together with other companies in the pharma/biotech business, could go through this crisis quite comfortable. And this will strengthen the relative position within an investors portfolio. Even if PARS is hit heavily on the beginning of the crisis (as it was the last few weeks), it will recover more quickly than the rest of the market. And this is going to lead to even more market interest. So in the long run, even a bear market could turn out to be positive for PARS. The only thing I fear right now is somebody using the chance to snatch up PARS at these discount prices, like Elan did with Neurex. In this case we all would loose. Hoping to see you win, Richard